Can I Ask Someone if They’re on Ozempic?

Weight loss now comes with a silent asterisk. When bodies change quickly or noticeably, assumptions often follow—and so does the desire to ask one potentially fraught question: Did medication play a role? GLP-1 drugs like Ozempic and Wegovy are testing the boundaries of body talk, leaving many unsure what’s fair or polite to ask, experts […]
Vance Desperately Clarifies He’s Not Trump’s ‘Fat’ Friend

Pool / Getty Images Vice President J.D. Vance hijacked a Cabinet meeting to make one thing clear: he is not President Donald Trump’s mysterious “fat” friend. The interruption came after Trump, 79, retold the tale at the White House Thursday of a portly businessman buddy who had been trying to lose weight using “the fat […]
There Are Many Types of Obesity, Says This GLP-1 Expert

A renowned physician-scientist says treatment is not one-size-fits-all.
I Hated Every Minute of My Two Weeks With Factor

Factor’s ready-to-eat meals looked sad and unappetizing, and I spent twice as much as usual on food while I used the service During my first week with Factor, I selected 11 recipes from the ready-to-eat meal delivery service to try. By Jodhaira Rodriguez Every year, I have a lengthy list of New Year’s resolutions. This […]
Fractyl Health, Inc. (GUTS) Discusses REMAIN-1 Midpoint Cohort Results on Revita for Weight Maintenance After GLP-1 Discontinuation Transcript
GLP-1 lawsuits over side effects are growing

The complaints number over 4,400, a fraction of the more than 31 million people taking the weight-loss drugs
GLP-1 momentum drives 79% pharma M&A surge

GLP-1 therapies helped drive a 79% year-over-year increase in strategic pharmaceutical M&A deal value through mid-November 2025, as drugmakers ramped up efforts to meet surging demand and expand their metabolic portfolios. According to Bain & Co.’s Global M&A Report 2026, the spike in activity reflects a shift in strategy: Acquirers are no longer focused solely […]
RHHBY’s 2025 Results Hit by Currency Headwinds, Sales Up 7% at CER

Swiss pharma giant Roche Holding AG’s RHHBY 2025 results were affected by currency headwinds. Sales totaled $74.4 billion, which missed the Zacks Consensus Estimate of $81.4 billion. Earnings per American Depositary Receipt of $2.94 also missed the Zacks Consensus Estimate of $3.06. The appreciation of the Swiss franc against most currencies, notably the US dollar, […]
MHRA updates guidance for GLP-1 prescribers and patients

Updated product information for healthcare professionals and patients regarding the small risk of severe acute pancreatitis in patients taking GLP-1s.
GLP-1 Receptor Agonists Tied to Lower Revision Rate After Functional Endoscopic Sinus Surgery

THURSDAY, Jan. 29, 2026 — Use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with reduced postoperative revision following functional endoscopic sinus surgery (FESS) for up to five years among patients with chronic…